• Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. 

  Szijgyarto, Z; Flach, KD; Opdam, M; Palmieri, C; Linn, SC; Wesseling, J; Ali, S; Bliss, JM; Cheang, MCU; Zwart, W; Coombes, RC (2019-01-24)

  PURPOSE: The prognostic and predictive values of the MAPK/AKT/ERα phosphorylation axis (pT202/T204MAPK, pT308AKT, pS473AKT, pS118ERα and pS167ERα) in primary tumours were assessed to determine whether these markers can ...
• Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. 

  Buus, R; Yeo, B; Brentnall, AR; Klintman, M; Cheang, MCU; Khabra, K; Sestak, I; Gao, Q; Cuzick, J; Dowsett, M (2018-09-04)

  BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ...
• SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. 

  Carreno, G; Boult, JKR; Apps, JR; Gonzalez-Meljem, JM; Haston, S; Guiho, R; Stache, C; Danielson, LS; Koers, A; Smith, LS; Virasami, A; Panousopoulos, L; Buchfelder, M; Jacques, TS; Chesler, L; Robinson, S; Martinez-Barbera, JP (2019-01-01)

  Pharmacological inhibition of the sonic hedgehog (SHH) pathway can be beneficial against certain cancers but detrimental in others. Adamantinomatous craniopharyngioma (ACP) is a relevant pituitary tumour, affecting children ...
• Does age matter? A comparison of health-related quality of life issues of adolescents and young adults with cancer. 

  Sodergren, SC; Husson, O; Rohde, GE; Tomasewska, IM; Griffiths, H; Pessing, A; Yarom, N; Hooker, L; Din, A; Darlington, AS; EORTC Quality of Life Group (2018-11)

  OBJECTIVE: Health-related quality of life (HRQoL) concerns of adolescents and young adults (AYAs) aged 14-25 years were compared with those of older adults (26-60 years) with cancer. METHODS: AYAs and older adults receiving ...
• A Life Put on Pause: An Exploration of the Health-Related Quality of Life Issues Relevant to Adolescents and Young Adults with Cancer. 

  Sodergren, SC; Husson, O; Rohde, GE; Tomasewska, IM; Vivat, B; Yarom, N; Griffiths, H; Darlington, A-S (2018-08)

  PURPOSE: In recent years, the assessment of health-related quality of life (HRQoL) has been recognized as particularly informative to healthcare providers. For adolescents and young adults (AYAs), the impact of a cancer ...
• Health-related quality of life among cancer patients in their last year of life: results from the PROFILES registry. 

  Raijmakers, NJH; Zijlstra, M; van Roij, J; Husson, O; Oerlemans, S; van de Poll-Franse, LV (2018-10)

  PURPOSE: The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS: Between 2008 and 2015, ...
• Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL). 

  Dearnaley, D; Griffin, CL; Lewis, R; Mayles, P; Mayles, H; Naismith, OF; Harris, V; Scrase, CD; Staffurth, J; Syndikus, I; Zarkar, A; Ford, DR; Rimmer, YL; Horan, G; Khoo, V; Frew, J; Venkitaraman, R; Hall, E (2018-12-06)

  PURPOSE: To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. METHODS AND MATERIALS: In this phase ...
• Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. 

  Moreno, L; Casanova, M; Chisholm, JC; Berlanga, P; Chastagner, PB; Baruchel, S; Amoroso, L; Gallego Melcón, S; Gerber, NU; Bisogno, G; Fagioli, F; Geoerger, B; Glade Bender, JL; Aerts, I; Bergeron, C; Hingorani, P; Elias, I; Simcock, M; Ferrara, S; Le Bruchec, Y; Slepetis, R; Chen, N; Vassal, G (2018-09)

  BACKGROUND: nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with ...
• Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. 

  Johnston, S; Puhalla, S; Wheatley, D; Ring, A; Barry, P; Holcombe, C; Boileau, JF; Provencher, L; Robidoux, A; Rimawi, M; McIntosh, SA; Shalaby, I; Stein, RC; Thirlwell, M; Dolling, D; Morden, J; Snowdon, C; Perry, S; Cornman, C; Batten, LM; Jeffs, LK; Dodson, A; Martins, V; Modi, A; Osborne, CK; Pogue-Geile, KL; Cheang, MCU; Wolmark, N; Julian, TB; Fisher, K; MacKenzie, M; Wilcox, M; Huang Bartlett, C; Koehler, M; Dowsett, M; Bliss, JM; Jacobs, SA (2019-01-20)

  PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination ...
• Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

  Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)

  Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
• A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. 

  Mateo, J; Olmos, D; Dumez, H; Poondru, S; Samberg, NL; Barr, S; Van Tornout, JM; Jie, F; Sandhu, S; Tan, DS; Moreno, V; LoRusso, PM; Kaye, SB; Schöffski, P (2016-04-12)

  BACKGROUND: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by ...
• Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. 

  Frezza, AM; Jones, RL; Lo Vullo, S; Asano, N; Lucibello, F; Ben-Ami, E; Ratan, R; Teterycz, P; Boye, K; Brahmi, M; Palmerini, E; Fedenko, A; Vincenzi, B; Brunello, A; Desar, IME; Benjamin, RS; Blay, JY; Broto, JM; Casali, PG; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Mir, O; Rutkowski, P; Wagner, AJ; Anurova, O; Collini, P; Dei Tos, AP; Flucke, U; Hornick, JL; Lobmaier, I; Philippe, T; Picci, P; Ranchere, D; Renne, SL; Sbaraglia, M; Thway, K; Wagrodzki, M; Wang, W-L; Yoshida, A; Mariani, L; Kawai, A; Stacchiotti, S (2018-09-01)

  Importance: Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the ...
• Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. 

  Bisogno, G; Jenney, M; Bergeron, C; Gallego Melcón, S; Ferrari, A; Oberlin, O; Carli, M; Stevens, M; Kelsey, A; De Paoli, A; Gaze, MN; Martelli, H; Devalck, C; Merks, JH; Ben-Arush, M; Glosli, H; Chisholm, J; Orbach, D; Minard-Colin, V; De Salvo, GL; European paediatric Soft tissue sarcoma Study Group (2018-08)

  BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug ...
• Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). 

  Shi, Q; Schmitz, N; Ou, F-S; Dixon, JG; Cunningham, D; Pfreundschuh, M; Seymour, JF; Jaeger, U; Habermann, TM; Haioun, C; Tilly, H; Ghesquieres, H; Merli, F; Ziepert, M; Herbrecht, R; Flament, J; Fu, T; Coiffier, B; Flowers, CR (2018-09-01)

  Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed ...
• Detection of circulating tumour cell clusters in human glioblastoma. 

  Krol, I; Castro-Giner, F; Maurer, M; Gkountela, S; Szczerba, BM; Scherrer, R; Coleman, N; Carreira, S; Bachmann, F; Anderson, S; Engelhardt, M; Lane, H; Evans, TRJ; Plummer, R; Kristeleit, R; Lopez, J; Aceto, N (2018-08)

  Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular ...
• RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. 

  Nava Rodrigues, D; Casiraghi, N; Romanel, A; Crespo, M; Miranda, S; Rescigno, P; Figueiredo, I; Riisnaes, R; Carreira, S; Sumanasuriya, S; Gasperini, P; Sharp, A; Mateo, J; Makay, A; McNair, C; Schiewer, M; Knudsen, K; Boysen, G; Demichelis, F; de Bono, JS (2019-01-15)

  PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments. Intrapatient genomic ...
• Association between information provision and supportive care needs among ovarian cancer survivors: A cross-sectional study from the PROFILES registry. 

  Rietveld, MJA; Husson, O; Vos, MCC; van de Poll-Franse, LV; Ottevanger, PBN; Ezendam, NPM (2018-08)

  OBJECTIVE: To examine the association between satisfaction with perceived information provision during diagnosis and treatment and supportive care needs in ovarian cancer survivors. METHODS: In 2012, women (n = 348) diagnosed ...
• Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. 

  Jones, RL; Le Cesne, A; Ibrahim, T; Garcia Del Muro, X; Menge, F (2018-12)

  INTRODUCTION: Health-related quality of life (HRQoL) is a patient-reported outcome that addresses patients' perceptions of symptoms across physical, emotional, cognitive and social domains. As HRQoL is currently rarely ...
• Health economic impact of liquid biopsies in cancer management. 

  IJzerman, MJ; Berghuis, AMS; de Bono, JS; Terstappen, LWMM (2018-12)

  INTRODUCTION: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a ...
• Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. 

  Athauda, A; Watkins, D; Mohammed, K; Chau, I; Starling, N; Rao, S; Tait, D; Aitken, K; Cunningham, D (2018-10)

  BACKGROUND/AIM: Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics ...

View more